Investigational Scan for Localized Pancreatic Cancer
This study is testing a new type of scan, called 68Ga-FAPI-46 PET/CT, for people with pancreatic cancer that has not spread (localized pancreatic ductal adenocarcinoma). This scan helps doctors see special cells called cancer-associated fibroblasts (CAFs) that are often found near tumors. The 68Ga-FAPI-46 is a special chemical that attaches to these CAFs, making them visible on the PET/CT scan. The goal is to see how well this scan can find and measure these CAFs, and how the scan results relate to other markers of the cancer. You might be able to join if you are an adult with newly diagnosed localized pancreatic cancer that doctors plan to remove with surgery, and you are generally in good health. The study aims to understand if this scan can help predict how well treatments will work. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 130 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would receive 68Ga-FAPI-46 intravenously, then have PET/CT scans at the start, up to two more scans during standard treatment, and one scan before surgery if applicable.
- Compensation
- Not stated in the trial record.
- Follow-up
- After your study treatment, you would be followed for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
At a glance
Conditions
NCT05518903
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic in Rochester
Rochester, Minnesotastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Ajit H. Goenka, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Diagnostic performance of fibroblast-activation-protein-inhibitors (FAPI) positron emission tomography (PET) for detection and quantification of cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma (PDA)Up to 5 years
Using surgical immunohistochemistry (IHC) as gold standard.
- Relationship between 68Ga-FAPI-46 PET metrics in PDAUp to 5 years
Relationship between 68Ga-FAPI-46 PET metrics assessed
- Relationship between 68Ga-FAPI-46 PET metrics and cancer antigen 19-9 (CA19-9) biomarkers in PDAUp to 5 years
Relationship between 68Ga-FAPI-46 PET metrics and cancer antigen 19-9 (CA19-9) being assessed.
- Relationship between 68Ga-FAPI-46 PET metrics and Kirsten rat sarcoma (KRAS), circulating tumor deoxyribonucleic acid (ctDNA) biomarkers in PDAUp to 5 years
Relationship between 68Ga-FAPI-46 PET metrics and Kirsten rat sarcoma (KRAS), circulating tumor deoxyribonucleic acid (ctDNA) being assessed.
- Relationship between 68Ga-FAPI-46 PET metrics and staging examinations in PDAUp to 5 years
Relationship between 68Ga-FAPI-46 PET metrics and fludeoxyglucose F-18 (FDG) PET staging exam being assessed.
- Relationship between 68Ga-FAPI-46 PET metrics and staging examinations in PDAUp to 5 years
Relationship between 68Ga-FAPI-46 PET metrics and magnetic resonance imaging (MRI) staging exam being assessed.